Enanta Pharmaceuticals Inc (ENTA)

[willyw]

https://seekingalpha.com/article/4512678-enanta-slow-drip

A very worth while reply to the article is in a first response in the reply section.
The SA article seems to ignore the Enanta covid candidate EDP-325.
Per J.Luly CEO the SAD & MAD dosing studies- and phase 1 of testing of the covid drug EDP 325 will be done in the 2nd quarter, and are presumed to be starting Phase 2 in the 3rd quarter.
One could surmise that if indeed EDP 325 is able to prove once a day ritonovir free dosing that it could soon be shown to be a best in class covid drug.

Per Enanta; " Fast Track designation [of EDP-325] enables more frequent communication with the FDA and eligibility for FDA programs such as priority review and rolling review, if relevant criteria are met. "
More clarity on what this means exactly could come in the next few months.

In short, the article took pains to ignore any of Enanta's pipeline other than RSV.
It seems to me that if the covid candidate is successful it could have more value- and sooner than the RSV pipeline. If that were the case it would seem a glaring omission in the article.